Camurus stock

CAMX · Nasdaq Stockholm · SEK

Compare Camurus
kr 739.50Change from previous close: −0.07%Absolute change: −kr 0.50

Close · November 20, 2026

Price history

+20.34% over the period

1 year: from kr 614.50 (November 20, 2025) to kr 739.50 (November 20, 2026), +20.34%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026kr 739.50
October 30, 2026kr 673.00
September 30, 2026kr 624.50
August 31, 2026kr 583.50
July 31, 2026kr 617.50
June 30, 2026kr 565.50
May 29, 2026kr 526.50
April 30, 2026kr 531.00
March 31, 2026kr 467.00
February 27, 2026kr 503.00
January 30, 2026kr 667.50
December 30, 2025kr 616.00
November 28, 2025kr 617.00
November 20, 2025kr 614.50

At a glance

  • The company

    Develops and commercializes medicines for severe and chronic diseases including opioid dependence, pain, and metabolic and endocrine disorders

  • Latest results

    Quarter to September 30, 2026 · EPS kr 4.53 (estimate kr 4.12)

TickerLandia's take on Camurus

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 430.80
52-wk highkr 750.00

−1.40% from the 52-week high

Analysts · 7 analysts

Average targetkr 850.00+14.94% vs. price

Buy 7 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Camurus

Compared with similar companies: very high financial strength and very strong momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Camurus is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Camurus's P/E today is 60.3, below the median of its last 4 fiscal years (75.1; between 50.2 and 260.4 from 2022 to 2025). Camurus's P/E (trailing 12 months): 58.7, +55% against the median of a group of 9 similar companies (38.0).

P/E compared with its history

Compared with 9 similar companies

Camurus's metrics compared with similar companies
MetricCamurusPosition in the groupBand
P/E (trailing 12 months)58.7Middle
Forward P/E48.1Middle
Operating margin37.4%High
ROE16.6%Middle
Debt/equity0.02Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Camurus. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 702.08M

Latest quarter · Q2 2026

Net income

kr 240.83M

Latest quarter · Q2 2026

Quarterly net margin

34.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 44.04B
P/E
58.7
EPS
kr 12.60
Volume
75.36K
Daily trading
€7.15M
Dividend yield
0.00%

How Camurus is changing

All results
  • Revenue grew 46.5% a year on average over the last 5 years

  • Operating margin rose from 7.5% to 39.1%

  • Profits turn into cash: free cash flow equal to 106% of net income

Returns

Camurus returns

kr 1,000 invested in Camurus 5 years ago, on November 22, 2021, would be worth kr 4,428 today: +342.81% in total, +34.71% per year. This is the price return only: dividends are excluded.

PeriodCamuruskr 1,000 becomes
1 month+11.37%kr 1,114
6 months+37.97%kr 1,380
Year to date+20.05%kr 1,200
1 year+20.34%kr 1,203
3 years+65.81%kr 1,658
5 years+342.81%kr 4,428
10 years+578.75%kr 6,788

Price only, without dividends. Calculate your investment

The chart in detail

Camurus: technical analysis

Camurus is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 0.7% below its all-time closing high (kr 745.00, November 13, 2026).

Trend
Upward
RSI (14 sessions)
68
Between 30 and 70
vs 200-session average
+28.14%

Support and resistance

Price areas where Camurus has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last pricekr 739.50
  3. Supportkr 698.83−5.50%3 touches, last on February 10, 2026
  4. Supportkr 659.00−10.89%2 touches, last on November 4, 2026
  5. Supportkr 642.50−13.12%5 touches, last on August 20, 2026

Volatility and risk

Volatility (60 sessions, annualised)
28.1%
Largest fall in the last year
−37.87%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Camurus: seasonality

Average monthly price change over 11 years

+0.9%Jan−2.0%Feb−1.6%Mar+9.3%Apr+3.4%May+5.6%Jun+6.7%Jul+2.0%Aug+5.6%Sep−3.8%Oct+8.1%Nov−3.3%Dec

Over the last 11 years, the strongest month for Camurus has been April: +9.34% on average, positive in 6 years out of 11. The weakest has been October: −3.83% on average, positive in 3 years out of 11. November, the current month, has been positive in 6 years out of 10 (+8.09% on average).

Show chart data
MonthAverageMedianPositive years
January+0.89%+1.08%6 of 11
February−2.02%−5.96%4 of 11
March−1.64%−3.35%5 of 11
April+9.34%+2.39%6 of 11
May+3.39%+3.65%6 of 11
June+5.60%+3.35%8 of 11
July+6.71%+9.20%7 of 11
August+1.97%+0.88%6 of 11
September+5.63%+5.71%7 of 11
October−3.83%−1.59%3 of 11
November+8.09%+4.52%6 of 10
December−3.33%−4.04%2 of 10

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Camurus and its competitors

Based in Lund, Sweden, Camurus was founded in 1991 and works as a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases. Its marketed products include Buvidal, used for opioid dependence and chronic pain, and Brixadi, used for opioid use disorder. The pipeline covers chronic pain, acromegaly, prostate cancer, polycystic liver disease and rare genetic obesity disorders, with partnerships involving Braeburn Pharmaceuticals, Rhythm Pharmaceuticals and Eli Lilly. The company serves customers in Europe, Africa, the Middle East, North America and Asia.

Headquarters
Lund, Sweden
Employees
323
Founded
1991
Chief executive
Fredrik Tiberg
Camurus and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
CamurusCAMX$4.32B37.4%58.7+37.97%
ABIVAXABVX$6.06B-6,270.4%—−38.78%
Bachem HoldingBANB$6.84B21.8%38.7−2.87%
Bavarian NordicBAVA$2.72B18.1%12.7+24.00%
BioArcticBIOA.B$2.66B19.6%259.5−6.59%
ALK-AbellóALK.B$7.79B26.6%38.0−7.14%

Same industry or related industries, similar size. Compare Camurus with its competitors · Full profile